Targeting protein stability with small molecules has emerged as an effective tool to control protein abundance in a fast, scalable and reversible manner. The technique involves tagging a protein of interest (POI) with a destabilizing domain (DD) specifically controlled by a small molecule. The successful construction of such fusion proteins may, however, be limited by functional interference of the DD epitope with electrostatic interactions required for full biological function of proteins. Another drawback of this approach is the remaining endogenous protein. Here, we combined the Cre-LoxP system with an advanced DD and generated a protein regulation system in which the loss of an endogenous protein, in our case the tumor suppressor PTEN, can be coupled directly with a conditionally fine-tunable DD-PTEN. This new system will consolidate and extend the use of DD-technology to control protein function precisely in living cells and animal models.
Introduction
Phosphatase and tensin homolog located on chromosome 10 (PTEN) is one of the most commonly mutated or deleted tumor suppressors in human cancer that is also causally linked to autism spectrum disorder [1, 2] . Changes in PTEN expression level leads to aberrant cell cycle progression as well as to alterations in cell migration [3, 4] , amongst other cellular responses. However, it is still a considerable challenge to ascertain the minimum alteration in PTEN level or activity that can cause the onset of tumor formation [5] or neurological changes [6] , or whether disease states can be ameliorated by reinstalling PTEN expression. Our ability to address questions of this nature are currently limited by the lack of experimental systems that allow the targeted and reversible regulation of PTEN [7] . We set out to exploit FKBP DD-technology to control PTEN protein function in a rapid, reversible and tunable manner. FKBP is a 12kDa FK506 binding protein, which is broadly expressed in various tissues and functions as a protein chaperone for newly synthesized polypeptides [8] . An engineered human FKBP has been developed that is able to bind a small synthetic ligand, Shld1, with 1000-fold selectivity over wild-type FKBP due to an amino acid (aa) substitution at F36 (F36V) [9] . A further aa substitution at L106 (L106P) causes FKBP to degrade rapidly in the absence of Shld1 [10] . Here, we further modified FKBP F36V/L106P by neutralizing highly charged surface amino acid residues, thereby eliminating the ability of the DD to interfere with electrostatic interactions required for full biological function of proteins. In case of PTEN, we demonstrate that FKBP F36V/L106P/E31S/D32S -PTEN permits rapid, reversible and tunable regulation of PTEN function in cellular and zebrafish models. We further eliminated a potential Cre pseudo-cleavage site within the FKBP Ã gene sequence to render the system compatible with the Cre-LoxP system. In conjunction, the two components will facilitate the study into protein network function, as FKBP-tagged proteins and conditional mouse alleles can be combined as required by the experimental set-ups.
Material and Methods
All animal procedures were approved by the local Animal Welfare and Ethics Review Body (King's College London) and were carried out in accordance with the Animals (Scientific Procedures) Act 1986, under license from the United Kingdom Home Office. 
Materials and cloning

Cell culture
PTEN null U87MG cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) media containing 10% FCS and 1% penicillin/streptomycin. The U87MG cell line stably expressing FKBP ÃÃ -PTEN was generated by G418 selection (500 μg/ml) and maintained in DMEM media containing 10% FCS and G418 (250 μg/ml). Cells were maintained at 37°C, 5% CO 2 in a humid atmosphere. Cerebral cortices were dissected from either CD1 or PTEN flox/flox E14.5 mouse embryos, dissociated in 0.33 mg/ml trypsin (Worthington, UK) in HBSS (Gibco, UK) for 15 min at 37°C and gently triturated with a fire polished Pasteur pipette in Neurobasal medium (Gibco, UK) supplemented with 2% fetal calf serum (FCS), 2% B27, 1% Glutamax and 1% penicillin/streptomycin (P/S). Neurons seeded at a density of 2000 cell/mm 2 on poly-Llysine coated culture plates.
Immuofluoresence staining U87MG cells stably expressing FKBP ÃÃ -PTEN were cultured on coverslips and fixed in 4% PFA in PBS for 20 min. Cells were then washed with PBS and blocked in blocking buffer (0.5% Triton X-100, 2% bovine serum albumin and 1% goat serum in PBS) for 1 h. Cells were incubated with rabbit anti-PTEN for 1h at room temperature and washed 3 times in PBS, and incubated with 
Transfection and nucleofection
Transfection of plasmid DNA into U87MG cells was carried out using GeneJuice (Novagen). Nucleofection of mouse primary cortical neurons was performed by using Amaxa (Fig 3) .
Western blotting
U87MG cells or primary neuron cultures was washed with ice-cold PBS and then lysed in lyses buffer (50 mM Tris-HCl, pH7.5, 150 mM NaCl; 1% Triton X-100; 500 μM NaF; 1 mM sodium orthovanadate; 1X protease inhibitor) for 10 min. Cell debris was removed by centrifugation at 13000 rpm for 10 min. The boiled supernatants supplemented with SDS loading sample buffer were loaded and run on 8% SDS-PAGE gel. Separated proteins were transferred to a nitrocellulose membrane. Blots were blocked in 5% skimmed milk powder in TBST (20 mM Tris; 150 mM NaCl; 0.1% Tween) for 1 h and incubated with primary antibody in 5% skimmed milk powder/TBST overnight at 4°C or for 1h at room temperature. The expression of proteins was visualized by HRP-conjugated secondary antibody and enhanced Chemiluminescence Kit (Pierce).
Colony formation assay
A single-cell suspension was prepared in 0.35% low melting point agar and plated (100 or 200 cells per well) in 24 well plates, which were pre-coated with 0.5% agar. Cell were then cultured for 3 weeks in media containing different concentrations of Shld1. Experiments were analyzed according to the protocol published by Franken et al. [11] . Plating efficiency was determined by the ratio of the number of colonies to the number of cells seeded.
Cell invasion assay
Cell invasion assay was performed using BioCoat™ invasion chamber (BD Biosciences) with 8μm pore, according to the manufacturer's instructions (BD Biosciences) with minor modifications. 0.5 ml of cell suspension (2.5x10 4 cells per well) prepared in serum-free media was added on rehydrated 24-well BioCoat™ Matrigel™ Invasion Chambers, which were placed in 24-well plate containing normal culture media (DMEM plus 10% FBS), and incubated in a humidified tissue culture incubator for 19 h, at 37°C, 5% CO 2 atmosphere. The cells were fixed with 4% PFA, permeabilized with 100% methanol for 20 min and stained with 0.05% crystal violet for 10 min. The cells and matrigel on the upper surface of the Matrigel Invasion Chambers were removed by scrubbing with cotton buds. Invasive cells were counted under microscope in 10 fields for each treatment. 
Statistical analysis
The migration of the injected U87MG cells stably expressing FKBP ÃÃ -PTEN in fish embryos in presence or absence of Shld1 were analysed in a similar way to fluorescent protein diffusion profiles [12] using the Radial Profile Plot plug-in of ImageJ. The concentric movement of cells away from a central point was quantified as a measure of increased fluorescence intensity at a distance from the central point over time. Curve fitting was carried out in Excel using the ). The average migration index of control group (without Shld1 treatment, n = 13) is compared with that of Shld1 treated group (n = 11). The size of tumor mass was measured by ImageJ. The average ratio of tumour mass size (1 dpi/0 dpi) was calculated and analyzed by Excel1 and SPSS using student two tailed t-test ÃÃ p<0.01; ÃÃÃ p<0.001.
Results
We fused PTEN at the C-terminus of the FKBP F36V/L106P -based DD (FKBP F36V/L106P will be referred to as FKBP Ã ) using a 12 aa linker sequence (-SSSSFEFALLPD-). We proposed that in the absence of Shld1, FKBP Ã would be rapidly degraded by the ubiquitin proteasome system [13] , resulting in the loss of FKBP Ã -PTEN fusion protein, whereas addition of Shld1 will stabilize the protein and inhibit PI3K/Akt signaling (Fig 1a) . Although expression levels of the FKBP Ã -linker-PTEN fusion demonstrated Shld1 dependency, the protein did not alter PI3K/ Akt signaling (Fig 1b) . FKBP Ã has been successfully used to regulate a number of different proteins, including cdc42 [14] , RhoA [14] , and MLYCD [15] , with no reported interference in their activity. We therefore surmised that the linker might not be suitable for generating biological active FKBP Ã -PTEN. Based on available knowledge regarding linker optimization [16, 17] , we composed a number of different peptide sequences with the aim of restoring PTEN activity in the FKBP Ã -linker-PTEN fusion protein (Fig 1c) . However, the most theoretically effective linkers [17] , a helix forming linker or a long flexible linker, did not restore PTEN activity as verified by analyzing pAkt levels in PTEN-null U87MG glioblastoma cells transfected with linker variants (Fig 1d) . In contrast, a linker containing the unique cyclic imino acid proline, which is unable to form hydrogen bonds to surrounding amino acids, was able to slightly improve PTEN activity (linker sequence 4, Fig 1d) . This limited success in restoring PTEN activity using linker optimization suggest that other mechanisms impede biological function of the phosphatase when presented in the FKBP Ã -PTEN fusion protein.
FKBP surface engineering restores PTEN activity of the FKBP-PTEN fusion protein
We considered the possibility that FKBP Ã might directly interfere with PTEN activity by blocking substrate access to the active site of the enzyme, which consists of a large pocket with positive charges that accommodates the PTEN phosphoinositide substrates (Fig 2a) . Indeed, the electrostatic potential maps of the PTEN surface (PDB ID: 1d5r) and the FKBP Ã surface (PDB ID: 1BL4) revealed complementary charge distributions of the PTEN substrate binding region and large negatively charged protrusions present on the FKBP Ã surface (Fig 2a) . Therefore, we engineered the FKBP Ã surface such that the charged regions were neutralized by replacing two acidic amino acid residues (E31 and D32) with basic amino acid residues (Arg or Lys), with polar uncharged residues (Ser), with hydrophobic residues (Val or Ala), or with the small amino acid Gly (Fig 2b) . Transfection of FKBP Ã -PTEN surface engineered variants into U87MG cells demonstrated that FKBP Ã modifications containing the aa substitutions E31S/ D32S, E31G/D32G or E31A/D32A (Fig 2b, PTEN variants 4 , 6, 7) resulted in Shld1 dependent regulation of PTEN activity towards PI3K/Akt signaling. However, only the E31S/D32S FKBP Ã mutant was efficiently stabilized by Shld1 (Fig 2c) . Hereafter, we refer to FKBP ÃE31S/D32S -PTEN as FKBP ÃÃ -PTEN. As the expression level of stabilized FKBP ÃÃ -PTEN defines the dynamic range of the scalability of the FKBP ÃÃ -PTEN regulation system, we exploited the strong CAG promoter sequence, a combination of the CMV early enhancer element and the chicken beta-actin promoter to drive FKBP ÃÃ -PTEN expression. Subcloning of the FKBP ÃÃ -PTEN cassette into a pCAG vector increased the level of protein expression and activity of FKBP ÃÃ -PTEN to a level comparable to GFP-PTEN (Fig 2d) .
Engineered FKBP** permits rapid, reversible and tunable regulation of PTEN function in cellular and zebrafish models
To further characterize the scalability, speed and reversibility of FKBP ÃÃ -PTEN in response to Shld1, we generated a U87MG cell line stably expressing FKBP ÃÃ -PTEN under the control of the CAG promoter (Fig 3) . Immunofluorescence labeling of these cells revealed that FKBP ÃÃ -PTEN was robustly stabilized following the addition of Shld1, and this stabilization could be abolished by Shld1 washout (Fig 3a and 3b) . FKBP ÃÃ -PTEN protein levels were gradually upregulated with increasing Shld1 concentration, resulting in a concomitant decrease in phosphorylated Akt, indicating that PI3K signaling can be fine-tuned by altering the level of FKBP ÃÃ -PTEN (Fig 3c) . The time-dependent stabilization profile of FKBP ÃÃ -PTEN showed that the engineered FKBP ÃÃ responded within a few hours of addition of Shld1 and reached a plateau after 8 h (Fig 3b) . Thus, the stabilization kinetics of FKBP ÃÃ is comparable to, or even faster than that of FKBP Ã [14] . We also discovered a rapid turnover of FKBP ÃÃ -PTEN within a few hours after the removal of Shld1 (Fig 3b) . (Fig 3d) . Thus, Shld1 can be used to fine tune PTEN activity to inhibit tumor growth and tumor cell division.
To investigate whether Shld1 can induce FKBP ÃÃ -PTEN stabilization and control biological responses in vivo, we used an established zebrafish metastasis model [20] , and microinjected the FKBP ÃÃ -PTEN U87MG cells, either pre-stained with DiI or transfected with RFP, into the perivitelline cavity of 2 days post fertilization (dpf) zebrafish larvae. Larvae were then transferred into Danieau's solution with or without 4μM Shld1. Images of larvae were taken immediately after injections and 24h post-injection (Fig 4a) . The migration indices and the increase in tumor mass size of transplanted cells were quantified over this time-course. These experiments demonstrated that Shld1 is effective in stabilizing FKBP ÃÃ -PTEN in zebrafish larvae, resulting in inhibition of invasion and growth of FKBP ÃÃ -PTEN U87MG cells (Fig 4b) . They also show for the first time that DD-systems can be used effectively to manipulate protein levels on demand in the zebrafish.
Codon optimization of FKBP** establishes a conditional fine-tuning protein regulation system
In order to achieve advanced regulation of protein function, it would be desirable to combine tunable FKBP ÃÃ -PTEN with established systems enabling precise control of gene expression, such as the Cre/LoxP system (Fig 5a) . For this purpose, FKBP ÃÃ -PTEN was subcloned immediately downstream of the second LoxP site of the LoxP-Stop-LoxP (LSL) cassette. We tested the pCAG-LSL-FKBP ÃÃ -PTEN construct in mouse cortical neuronal primary cultures by transient co-transfection with Cre-IresRFP (or, in control experiments, RFP). The FKBP ÃÃ -PTEN fusion protein was only detectable by western blotting in the presence of Cre, and following application of the synthetic ligand Shld1 (Fig 5b) . Surprisingly, when Cre and FKBP ÃÃ -PTEN were coexpressed, the anti-PTEN antibody also identified a distinct protein band with lower molecular weight than full-length FKBP ÃÃ -PTEN, which was stable even in the absence of Shld1. We reasoned that this protein could represent a form of FKBP ÃÃ -PTEN with a truncation in the FKBP ÃÃ domain which allows it to escape Shld1 regulation. A mechanism involving Credependent truncation of FKBP ÃÃ -PTEN suggests that these two regulation systems could be incompatible. Due to the sequence similarity of FKBP Ã and the engineered FKBP ÃÃ domain it is likely that this might also be true of the parental DD system. We therefore investigated the potential sites of Cre action within the DD domain. Cre recombinase is an enzyme known to catalyze site specific recombination events between two DNA recognition sites (LoxP sites) of 34 base pairs, which form a stem-loop-stem structure. We aligned the LoxP sequence with the human FKBP ÃÃ DNA sequence and found an 88.9% similarity between the loop region of LoxP and the sequence surrounding the third ATG of the human FKBP ÃÃ gene (M3L cta and LoxP rev ) (Fig 5c) . Consequentially, the third ATG 
Discussion
The targeting of protein stability with small molecules has emerged as a strategy in synthetic biology to ascertain protein function. The technique involves genetically endowing the protein of interest with a protein destabilizing domain specifically and reversibly controlled by a small molecule, so that the stability of the fusion protein is dependent upon the sequence of the DDs rather than that of the POI. An established DD sequence is based on a modified FKBP (FKBP F36V/L106P ); however, one of the recurring problems associated is the possible interference of the FKBP F36V/L106P tag with electrostatic interactions, as well as the remaining unaffected endogenous protein, which interfered here with the phosphatase activity of PTEN. We modified FKBP F36V/L106P by neutralizing highly charged surface amino acid residues.
This modification resolved the problem of electrostatic interference by ensuring the full biological activity of PTEN, which retains highly charged amino acids within the active site essential for function. We demonstrate that our newly generated fusion protein (FKBP ÃÃ -PTEN) permits rapid, reversible and tunable regulation of protein function in cellular as well as, for the first time, in zebrafish models. Furthermore, we have rendered the system compatible with the Cre-LoxP system. We identified and eliminated a potential Cre pseudo-cleavage site within the FKBP gene. Following Cre-mediated recombination, expression of the FKBP ÃÃ -PTEN gene is achieved. The system now provides two layers of control over protein levels and activity: the first operating at transcriptional and the second at posttranslational level.
The development of the FKBP-Shield1/Cre-LoxP system offers unique possibilities to manipulate protein function in vitro and in vivo, by combining the loss of endogenous proteins directly with the expression of tunable versions. This system is compatible with the building of sophisticated protein regulation networks as FKBP ÃÃ -tagged proteins, as well as conditional mouse alleles can be selected and combined as required. Additionally, the system allows precise and effortless control over the re-installment of protein function following molecular deficits, thus offering a powerful means with which to address the reversibility of a number disease states, in particular those associated with developmental disorders. Therefore, this study consolidates and extends the use of DD-technology to manipulate protein function in a specific, fast, reversible and tunable manner.
